A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

November 3, 2026 updated by: Eli Lilly and Company

A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared With Mirikizumab in Adults With Moderately to Severely Active Crohn's Disease

The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD). This study is part of the IIBD master protocol and will last approximately 62 weeks.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: There may be multiple sites in this clinical trial. (Add "This 1-877-CTLILLY (1-877-285-4559) or
  • Phone Number: 1-317-615-4559
  • Email: clinical_inquiry_hub@lilly.com

Study Locations

      • Ghent, Belgium, 9000
        • Recruiting
        • AZ Maria Middelares
        • Principal Investigator:
          • Didier Baert
      • Ghent, Belgium, 9000
        • Not yet recruiting
        • UZ Gent
        • Principal Investigator:
          • Jeroen Geldof
      • Leuven, Belgium, 3000
        • Recruiting
        • UZ Leuven
        • Principal Investigator:
          • Bram Verstockt
      • Roeselare, Belgium, 8800
        • Recruiting
        • AZ Delta vzw
        • Principal Investigator:
          • Filip Baert
      • Campinas, Brazil, 13092-133
        • Recruiting
        • Loema Instituto de Pesquisa Clinica
        • Principal Investigator:
          • Joaquim Simoes Neto
      • Caxias do Sul, Brazil, 95070-560
        • Recruiting
        • Fundação Universidade de Caxias do Sul (FUCS)
        • Principal Investigator:
          • Eduardo Brambilla
      • Curitiba, Brazil, 80430-180
        • Recruiting
        • Centro Digestivo de Curitiba
        • Principal Investigator:
          • Odery Ramos Júnior
      • Marília, Brazil, 17504-072
        • Recruiting
        • Centro de Pesquisa Clínica de Marília - CPCLIM
        • Principal Investigator:
          • FABIO TEIXEIRA
      • São Paulo, Brazil, 01236030
        • Recruiting
        • BR Trials - Ensaios Clinicos e Consultoria
        • Principal Investigator:
          • Roberto da Silva
      • São Paulo, Brazil, 01228-200
        • Recruiting
        • CPCLIN
        • Principal Investigator:
          • Adolpho Alexander da Silva
      • São Paulo, Brazil, 01228-000
        • Recruiting
        • CPHosp Medicina, Ensino e Pesquisa (CPQuali)
        • Principal Investigator:
          • Rafael Lages
      • São Paulo, Brazil, 04077-020
        • Recruiting
        • Clínica Hepatogastro JK
        • Principal Investigator:
          • Rodrigo Andrey Rocco
      • Vitória, Brazil, 29055450
        • Recruiting
        • CEDOES
        • Principal Investigator:
          • Felipe Ferreira
      • Greenfield Park, Canada, J4V 2H1
        • Not yet recruiting
        • Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre
        • Principal Investigator:
          • Andrew Wisniewski
      • Lethbridge, Canada, T1J 4G9
        • Not yet recruiting
        • Prairie Institute of Liver and Luminal Advanced Research Ltd (PILLAR)
        • Principal Investigator:
          • Kaleb Marr
      • London, Canada, N6K 1M6
        • Not yet recruiting
        • London Digestive Disease Institute
        • Principal Investigator:
          • Vipul Jairath
      • Vaughan, Canada, L4L 4Y7
        • Recruiting
        • Tdda Inc.
        • Principal Investigator:
          • David Ford
      • Changsha, China, 410011
        • Recruiting
        • The Second Xiangya Hospital of Central South University
        • Principal Investigator:
          • Xuehong Wang
      • Changzhou, China, 213000
        • Recruiting
        • Changzhou Second People's Hospital
        • Principal Investigator:
          • Wenjia LIU
      • Guangzhou, China, 510080
        • Recruiting
        • The First Affiliated Hospital, Sun Yat-sen University
        • Principal Investigator:
          • Baili Chen
      • Hangzhou, China, 310052
        • Recruiting
        • The Second Affiliated hospital of Zhejiang University school of medicine
        • Principal Investigator:
          • Yan Chen
      • Huizhou, China, 516001
        • Recruiting
        • Huizhou Central People's Hospital
        • Principal Investigator:
          • Huixin Chen
      • Suzhou, China, 215004
        • Recruiting
        • The Second Affiliated Hospital of Soochow University
        • Principal Investigator:
          • Wen Tang
      • Wenzhou, China, 325000
        • Recruiting
        • The Second Affiliated Hospital YuYing Childens Hospital of Wenzhou Medical university
        • Principal Investigator:
          • yi Jiang
      • Xiamen, China, 361000
        • Recruiting
        • Zhongshan Hospital Affiliated to Xiamen University
        • Principal Investigator:
          • Yanyun Fan
      • Zhenjiang, China, 212000
        • Recruiting
        • Affiliated Hospital of Jiangsu University
        • Principal Investigator:
          • Min Xu
      • Berlin, Germany, 10117
        • Not yet recruiting
        • Charité Universitaetsmedizin Berlin - Campus Mitte
        • Principal Investigator:
          • Christoph Jochum
      • Dachau, Germany, 85221
        • Suspended
        • Studienzentrum MVZ Dachau
      • Halle, Germany, 06108
        • Recruiting
        • Studiengesellschaft Mitteldeutschland GmbH
        • Principal Investigator:
          • Lars Fechner
      • Ludwigshafen, Germany, 67067
        • Recruiting
        • St. Marien- und St. Annastiftskrankenhaus
        • Principal Investigator:
          • Tanja Kuehbacher
      • Ulm, Germany, 89081
        • Not yet recruiting
        • Universitaetsklinikum Ulm
        • Principal Investigator:
          • Jochen Klaus
      • Budapest, Hungary, 1082
        • Recruiting
        • Semmelweis Egyetem
        • Principal Investigator:
          • Pal Miheller
      • Budapest, Hungary, 1066
        • Recruiting
        • Geomedical Egészségügyi Központ
        • Principal Investigator:
          • Gabor Hegede
      • Tatabánya, Hungary, 2800
        • Recruiting
        • Komarom-Esztergom Varmegyei Szent Borbala Korhaz
        • Principal Investigator:
          • Samer Francis
      • Ashdod, Israel, 7747629
        • Recruiting
        • Assuta Ashdod Medical Center
        • Principal Investigator:
          • Adi Lahat-Zok
      • Haifa, Israel, 3109601
        • Recruiting
        • Rambam Health Care Campus
        • Principal Investigator:
          • Roni Weisshof
      • Jerusalem, Israel, 9103102
        • Recruiting
        • Shaare Zedek Medical Center
        • Principal Investigator:
          • Benjamin Koslowsky
      • Jerusalem, Israel, 9112001
        • Recruiting
        • Hadassah Medical Center
        • Principal Investigator:
          • ADAR ZINGER
      • Petah Tikva, Israel, 4941492
        • Recruiting
        • Rabin Medical Center
        • Principal Investigator:
          • Irit Avni-Biron
      • Ramat Gan, Israel, 5262100
        • Recruiting
        • Sheba Medical Center
        • Principal Investigator:
          • Asaf Levartovsky
      • Tsrifin, Israel, 7033001
        • Recruiting
        • Yitzhak Shamir Medical Center
        • Principal Investigator:
          • Vered Richter
      • Florence, Italy, 50134
        • Recruiting
        • Azienda Ospedaliera Universitaria Careggi
        • Principal Investigator:
          • Gabriele Dragoni
      • Milan, Italy, 20132
        • Not yet recruiting
        • Ospedale San Raffaele
        • Principal Investigator:
          • Silvio Danese
      • Monza, Italy, 20900
        • Not yet recruiting
        • Fondazione IRCCS San Gerardo dei Tintori
        • Principal Investigator:
          • Chiara Viganò
      • Negrar, Italy, 37024
        • Not yet recruiting
        • Ospedale Sacro Cuore Don G. Calabria
        • Principal Investigator:
          • Angela Variola
      • Roma, Italy, 00168
        • Not yet recruiting
        • Fondazione Policlinico Universitario Agostino Gemelli
        • Principal Investigator:
          • Franco Scaldaferri
      • Rozzano, Italy, 20089
        • Not yet recruiting
        • Humanitas
        • Principal Investigator:
          • Alessandro Armuzzi
      • Katowice, Poland, 40-600
        • Recruiting
        • Gyncentrum sp. z o.o. NZOZ Holsamed - oddział Libero
        • Principal Investigator:
          • Marek Olakowski
      • Krakow, Poland, 31-228
        • Recruiting
        • Centrum Medyczne Oslomed
        • Principal Investigator:
          • Anna Drozdz
      • Lublin, Poland, 20-582
        • Not yet recruiting
        • Medrise Sp. z o.o.
        • Principal Investigator:
          • Wit Danilkiewicz
      • Poznan, Poland, 60-324
        • Recruiting
        • Twoja Przychodnia PCM
        • Principal Investigator:
          • Ewa Furmanowska-Ladorska
      • Siedlce, Poland, 08-110
        • Recruiting
        • ETG Siedlce
        • Principal Investigator:
          • Anna Lewandowska
      • Szczecin, Poland, 71-434
        • Recruiting
        • Twoja Przychodnia SCM
        • Principal Investigator:
          • Beata Gawdis-Wojnarska
      • Szczecin, Poland, 71-685
        • Recruiting
        • Sonomed Sp. z o. o.
        • Principal Investigator:
          • Anna Wiechowska-Kozlowska
      • Warsaw, Poland, 04-501
        • Recruiting
        • Medical Network Spółka z o.o. WIP Warsaw IBD Point Profesor Kierkuś
        • Principal Investigator:
          • Jaroslaw Kierkus
      • Warsaw, Poland, 02-786
        • Not yet recruiting
        • WSD MEDI
        • Principal Investigator:
          • Michal Krogulecki
      • Zamość, Poland, 22-400
        • Recruiting
        • ETG Zamość
        • Principal Investigator:
          • Katarzyna Wojcik
    • Arizona
      • Scottsdale, Arizona, United States, 85259
        • Suspended
        • Mayo Clinic in Arizona - Scottsdale
    • California
      • Los Angeles, California, United States, 90035
        • Not yet recruiting
        • Biopharma Informatic, LLC
        • Principal Investigator:
          • Morris Silver, MD
      • Oxnard, California, United States, 93030
        • Recruiting
        • Om Research LLC
        • Principal Investigator:
          • Karen Simon
    • Colorado
      • Englewood, Colorado, United States, 80113
        • Recruiting
        • South Denver Gastroenterology
        • Principal Investigator:
          • Marcelo Kugelmas
    • Florida
      • Miami, Florida, United States, 33176
        • Recruiting
        • Gastro Health Research - Miami
        • Principal Investigator:
          • Lukasz Kwapisz
      • Miami Lakes, Florida, United States, 33015
        • Recruiting
        • Ezy Medical Research
        • Principal Investigator:
          • Hendry Perez-Pascual
    • Georgia
      • Atlanta, Georgia, United States, 30342
        • Recruiting
        • Atlanta Gastroenterology Associates - Peachtree Dunwoody
        • Principal Investigator:
          • Nitin Gupta
    • Illinois
      • Chicago, Illinois, United States, 60612
        • Not yet recruiting
        • Rush University Medical Center
        • Principal Investigator:
          • Atsushi Sakuraba
    • Kansas
      • Topeka, Kansas, United States, 66606
        • Recruiting
        • Cotton O'Neil Digestive Health Center
        • Principal Investigator:
          • Curtis Baum
    • Michigan
      • Wyoming, Michigan, United States, 49519
        • Not yet recruiting
        • Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinical Research Center
        • Principal Investigator:
          • Allan Coates
    • Missouri
      • St Louis, Missouri, United States, 63123
        • Recruiting
        • KAD Clinical Research
        • Principal Investigator:
          • Adrian Di Bisceglie
    • Nevada
      • Las Vegas, Nevada, United States, 89128
        • Recruiting
        • Vector Clinical Trials
        • Principal Investigator:
          • Christian Stone
    • Texas
      • Kingwood, Texas, United States, 77339
        • Recruiting
        • One of a Kind Clinical Research Center - Kingwood
        • Principal Investigator:
          • Sushovan Guha
      • San Antonio, Texas, United States, 78229
        • Recruiting
        • Southern Star Research Institute
        • Principal Investigator:
          • Jeff Bullock

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Participants must meet all the inclusion criteria in the IIBD master protocol, except the UC-specific criteria. In addition, they must meet the criteria below:

  • Participants taking glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), GLP-1/glucose-dependent insulinotropic polypeptide (GIP) RAs, GLP-1/glucagon (Gcg) RAs, GLP-1/GIP/Gcg RAs, or similar medications for approved indications will be permitted to enroll provided they are on a stable dose at the time of screening

Exclusion Criteria:

Participants are excluded from the study if any of the exclusion criteria in the IIBD master protocol, except the UC-specific criteria apply, or if any of the following criteria apply:

  • Must not have a hepatic disease

  • Must not have a history of any other bone disease that affects bone metabolism

  • Must not have had any of the following within the past 180 days before screening:

    • acute myocardial infarction
    • cerebrovascular incident
    • hospitalization for unstable angina
    • hospitalization due to congestive heart failure, or
    • coronary revascularization
  • Must not have received or will need any other prohibited medications as specified in the protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Mirikizumab

Study Period 1: Mirikizumab administered via IV. Study Period 2: Responders will receive mirikizumab SC.

Administered IV

Other Names:
  • LY3074828

Administered SC

Other Names:
  • LY3074828
Experimental: LY4395089 and Mirikizumab Co-Administration

Study Period 1: Co-administration of LY4395089 administered orally and mirikizumab administered IV.

Study Period 2: Responders will stop LY4395089 and receive mirikizumab SC.

Administered IV

Other Names:
  • LY3074828

Administered SC

Other Names:
  • LY3074828

Administered orally

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Participants with Crohn's Disease who Achieve Endoscopic Response
Time Frame: Baseline, Up to Week 12

The percentage of participants who achieve endoscopic response at week 12 of Study Period 1.

Baseline, Up to Week 12

Secondary Outcome Measures

Outcome Measure
Time Frame
Percentage of Participants who Achieve Clinical Remission
Time Frame: Baseline, Up to Week 12
Baseline, Up to Week 12
Percent Change from Baseline in Fecal Calprotectin
Time Frame: Baseline, Up to Week 12
Baseline, Up to Week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Contact Lilly at 1-877-CTLILLY (1-877-285-4559) or, Eli Lilly and Company

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 4, 2026

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

March 1, 2028

Study Registration Dates

First Submitted

March 16, 2026

First Submitted That Met QC Criteria

March 16, 2026

First Posted (Actual)

March 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 4, 2026

Last Update Submitted That Met QC Criteria

November 3, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 27810
  • J6Z-MC-CD01 (Other Identifier: Eli Lilly and Company)
  • J6Z-MC-IIBD (Other Identifier: Eli Lilly and Company)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

IPD Sharing Time Frame

Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

IPD Sharing Access Criteria

A research proposal should be approved by an independent review panel and researchers should sign a data sharing agreement.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe